Novartis AG’s Tasigna Surpasses Glivec In Leukemia Treatment

June 4, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis (NOVN.VX) said 18-month results from a study confirmed its Tasigna cancer drug is more efficient in slowing down chronic myeloid leukaemia (CLM) than older medicine Glivec.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase III

Novartis